每日顺铂同步高剂量放疗治疗Ⅲ期非小细胞肺癌患者
该研究回顾性纳入154例经18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描分期的ⅢA和ⅢB期非小细胞肺癌患者(2005-2015年),接受每日低剂量顺铂(6 mg/m2)同步24次2.75 Gy放疗至总剂量66 Gy。中位随访22个月,中位总生存期为36个月,1年、2年、3年和5年生存率分别为79%、61%、52%和40%,5年局部无复发生存率为55%,5年无转移生存率为53%,严重胃肠道疾病(3-5级)发生率为11%,严重呼吸、胸部和纵隔疾病(3-5级)发生率为8.4%。
要点
- 每日低剂量顺铂同步放疗的3年生存率为52%,5年生存率为40%。
- 3-5级严重胃肠道疾病发生率为11%,其中3级放射性食管炎为8.4%。
- 3-5级严重呼吸、胸部和纵隔疾病发生率为8.4%,其中3级放射性肺炎为1.3%。
核心结论
- 每日低剂量顺铂同步放化疗治疗局部晚期Ⅲ期非小细胞肺癌获得了有前景的总生存期(3年生存率52%,5年生存率40%)且毒性低。
- 淋巴结大体肿瘤体积、肿瘤大体肿瘤体积和性别是总生存期、治疗毒性和远处转移的预测因素。
研究设计与样本
- 回顾性选择2005-2015年经18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描分期的ⅢA和ⅢB期非小细胞肺癌连续患者154例。
- 同步放化疗方案为每日低剂量顺铂(6 mg/m2)联合24次2.75 Gy放疗至总剂量66 Gy。
主要发现
- 中位随访22个月(范围1-92个月),中位总生存期为36个月。
- 1年、2年、3年和5年生存率分别为79%(95%CI 73%-86%)、61%(95%CI 54%-70%)、52%(95%CI 43%-60%)和40%(95%CI 31%-51%)。
- 5年局部无复发生存率为55%(95%CI 44%-69%),5年无转移生存率为53%(95%CI 44%-65%)。
- 严重胃肠道疾病(3-5级)发生率为11%,其中3级放射性食管炎为8.4%;严重呼吸、胸部和纵隔疾病(3-5级)发生率为8.4%,其中3级放射性肺炎为1.3%。
- 总生存期的预测因素为淋巴结大体肿瘤体积(HR 1.007;95%CI 1.000-1.012)和性别(HR 0.500;95%CI 0.320-0.870),有利于女性。
关键数值与推荐
- 同步放化疗方案:每日低剂量顺铂6 mg/m2联合24次2.75 Gy放疗至总剂量66 Gy。
- 总生存期预测因素:淋巴结大体肿瘤体积(HR 1.007;95%CI 1.000-1.012)和性别(HR 0.500;95%CI 0.320-0.870,有利于女性)。
- 治疗毒性预测因素:淋巴结大体肿瘤体积(HR 1.010;95%CI 1.000-1.013)。
- 随访期间远处转移预测因素:肿瘤大体肿瘤体积(HR 1.002;95%CI 1.001-1.003)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to determine survival, local and distant control, toxicity, and prognostic factors in patients with stage III non-small cell lung cancer (NSCLC) treated with concurrent chemoradiation therapy (CCRT). METHODS AND MATERIALS: Consecutive patients with stage IIIA and IIIB NSCLC (N = 154) staged with 18F-fluorodeoxyglucose positron emission tomography/computed tomography were retrospectively selected (2005-2015). CCRT consisted of daily low-dose cisplatin (6 mg/m2) combined with 24 fractions of 2.75 Gy to a total dose of 66 Gy. RESULTS: During a median follow-up period of 22 months (range, 1-92 months) the median overall survival was 36 months. The 1-, 2-, 3-, and 5-year survival rates were 79% (95% confidence interval [CI], 73%-86%), 61% (95% CI, 54%-70%), 52% (95% CI, 43%-60%), and 40% (95% CI, 31%-51%), respectively. The local relapse-free survival at 5 years was 55% (95% CI, 44%-69%). Metastasis-free survival at 5 years was 53% (95% CI, 44%-65%). The incidence of severe gastrointestinal disorders (grade 3-5) was 11%, among which grade 3 radiation esophagitis was 8.4%. The incidence of severe respiratory, thoracic, and mediastinal disorders (grade 3-5) was 8.4%, among which grade 3 radiation pneumonitis was 1.3%. Predictors of overall survival were lymph node gross tumor volume (GTV) (hazard ratio [HR], 1.007; 95% CI, 1.000-1.012) and sex (HR, 0.500; 95% CI, 0.320-0.870) in favor of women. Although lymph node GTV was a predictor of treatment toxicity (HR, 1.010; 95% CI, 1.000-1.013), tumor GTV was the predictor for distant metastasis during follow-up (HR, 1.002; 95% CI, 1.001-1.003). CONCLUSIONS: CCRT with daily low-dose cisplatin for locally advanced stage III NSCLC resulted in promising overall survival (3-year survival rate of 52% and 5-year survival rate of 40%) with low toxicity. Lymph node GTV, tumor GTV, and sex were predictors of overall survival, treatment toxicity, and distant metastasis.
引用
- Dieleman EMT, Uitterhoeve ALJ, van Hoek MW, et al. Concurrent Daily Cisplatin and High-Dose Radiation Therapy in Patients With Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 30055239. doi:10.1016/j.ijrobp.2018.07.188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。